Our portfolio
Lodo Therapeutics

Natural product drug discovery platform

Lodo Therapeutics is creating a best-in-class natural product drug discovery platform for the discovery, biosynthesis, and characterization of new, genetically encoded small molecules.
Website
  • Domain
    Life Sciences
  • Investment type
    Direct equity
  • Status
    Exit
  • Initial investment
    Series A
  • Partnered in
    2015
  • Headquarters
    USA
  • Program strategy
    Discovery & Translational Sciences
Portfolio news
In 2021, Lodo Therapeutics was acquired by Zymergen. Zymergen was then acquired by Ginkgo Bioworks in 2022.

More about our work

Our focus

Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.

Investment approach

Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.

Our team

We bring depth of experience to every investment, with a proven track record across sectors and scale.